Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

377P - Comparison of current guidelines and real-world evidence data for the treatment of glioblastoma across Europe

Date

16 Sep 2021

Session

ePoster Display

Topics

Cytotoxic Therapy

Tumour Site

Central Nervous System Malignancies

Presenters

Carrmen Escorial

Citation

Annals of Oncology (2021) 32 (suppl_5): S516-S529. 10.1016/annonc/annonc674

Authors

C. Escorial, L. Hoyer, F. Tetzlaff

Author affiliations

  • Real World Solutions, Bu Oncology, IQVIA Commercial GmbH & Co. OHG/IQVIA RDS GmbH - Zentrale, 60549 - Frankfurt am Main/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 377P

Background

Glioblastoma (GBM) is the most frequent primary malignant brain tumor in adults. The standard of care in Europe is temozolomide (TMZ) ± lomustin and radiotherapy. In other countries (USA, Canada, and Switzerland) bevacizumab is approved for GBM, since it showed improved progression-free survival, however no overall survival increase was proven. Furthermore, no standard of care is established in recurrent or progressive cases due to the complex heterogeneity of the disease. Due to the limited treatment options in Europe and considering that bevacizumab is approved for GBM in other countries, treatment patterns based on real-world data will be analyzed to detect potential off-label use of bevacizumab in the UK and EU4 countries.

Methods

Anonymized patients-level data collected through a large web-based survey between January 2017 and December 2020 was used. The study reported patient case history information across all cancer types in EU4 (France, Germany, Italy, Spain) & UK. Treatment information on 3.657 glioblastoma drug treated patients was analyzed.

Results

The analysis of the treatment landscape of glioblastoma in Europe showed a share of 99% of (neo-)adjuvant and 89% of 1st line patients treated with TMZ. However, when analyzing the 2nd line only 17% of patients were treated with TMZ. On the other hand, bevacizumab treated patients represented a 0,1% in the (neo-)adjuvant setting, 6% in 1st line which raised to 59% in the 2nd line. More specifically a significant increase of bevacizumab treated patients from the 1st to the 2nd line was observed in Spain (1st Line: 5%, 2nd Line: 73%) and France (1st Line: 12%, 2nd Line: 90%). Furthermore, 73% of patients in Spain and 75% of patients in France changed therapy from TMZ to bevacizumab due to local/distant progression.

Conclusions

Conforming to the European guidelines, the majority of patients in (neo-)adjuvant and 1st line setting are treated with TMZ. However, in France and Spain a high off-label use of bevacizumab has been identified in the 2nd line. Most of those patients arise from an unsuccessful TMZ treatment due to progression of the disease.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

IQVIA Global Oncology, Central, East & South Europe.

Funding

IQVIA Global Oncology, Central, East & South Europe.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.